Valvular & structural heart disease
Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED Transcatheter Aortic Valve Replacement (TAVR) Randomized Clinical Trial
Authors' conclusion
Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the US cohort but not in the OUS cohort.
Study context
- Population
- Patients with symptomatic AS treated with transfemoral TAVR, 51 hospitals in the US, Europe and Australia, 2020–2022US 1833
- Participants
- 3,000 patients
- Comparison
- TAVR with cerebral embolic protection (CEP) vs TAVR alone, by geographic region
- Primary endpoint
- All stroke events
- Follow-up
- Hospital discharge or 72 hours post-TAVR, whichever came first
Methodological detailsprospective, postmarket, multicentre (51 hospitals), exploratory post hoc subgroup analysis by geographic region, Data analysed August to October 2024
- Prospective
- Postmarket
- Multicentre (51 hospitals)
- Exploratory post hoc subgroup analysis by geographic region
- Data analysed August to October 2024
Primary result
As reported in the abstract
Stroke by geographic region (US vs OUS cohort)
US cohort: CEP vs TAVR alone, relative risk reduction for overall stroke
50%
US cohort: CEP vs TAVR alone, relative risk reduction for disabling stroke
73%
Further findings
Stroke within 72 h after TAVR or before discharge (main trial)
- No significant difference between CEP and control; no interaction by geographic region
Original publication
Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial. JAMA Cardiol. Published 1 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →